|Articles|October 13, 2016

PE Media Planner 2017

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Pharmaceutical Executive Daily: President Trump Imposes 100% Tariff for Branded Pharmaceuticals

ByNicholas Jacobus

April 3rd 2026

The high cost of medicine in the United States is not a new phenomenon, but its root causes are complex and deeply embedded in the nation’s legal and regulatory architecture. . Credit: Stock.Adobe.com/Cagkan

The New Era of U.S. Pharmaceutical Pricing: From Policy Upheaval to Strategic Adaptation

ByPartha Anbil

April 3rd 2026

Pfizer and BioNTech Pause Covid Vaccine Study Following Low Enrollment Totals

ByNicholas Jacobus

April 3rd 2026

Scaling AI's Promise in Healthcare: The Time is Now

ByMichael Christel,Pratap Khedkar, PhD

April 3rd 2026

Expanding Access to Whole-Genome Testing for Children: Q&A with Drs. Ryan Taft and Stacy Musone

ByMike Hollan,Dr. Ryan Taft,Stacy Musone

April 3rd 2026

PE Media Planner 2017

Newsletter

Related Content

Pharmaceutical Executive Daily: President Trump Imposes 100% Tariff for Branded Pharmaceuticals

The New Era of U.S. Pharmaceutical Pricing: From Policy Upheaval to Strategic Adaptation

Pfizer and BioNTech Pause Covid Vaccine Study Following Low Enrollment Totals

Scaling AI's Promise in Healthcare: The Time is Now

Expanding Access to Whole-Genome Testing for Children: Q&A with Drs. Ryan Taft and Stacy Musone

Trending on PharmExec

President Trump Imposes 100% Tariffs on Branded Pharmaceuticals

Why ‘Boring’ AI Could Save Healthcare When the Bubble Bursts

Pfizer and BioNTech Pause Covid Vaccine Study Following Low Enrollment Totals

Pharmaceutical Executive Daily: President Trump Imposes 100% Tariff for Branded Pharmaceuticals

The New Era of U.S. Pharmaceutical Pricing: From Policy Upheaval to Strategic Adaptation